Preferred Label : NY-ESO-1 Protein/Microparticle MDP/Bacterial DNA-containing MIS416 Vaccine;
NCIt synonyms : NY-ESO-1 Protein with MIS416; NY-ESO-1 Protein/MIS416;
NCIt definition : A combination preparation composed of a protein derived from the human tumor-associated
antigen (TAA) cancer-testis antigen 1 (NY-ESO-1) and a microparticle combining two
immune-modifying components derived from the bacterium Propionibacterium acnes, a
bacterial cell wall component that is rich in muramyl dipeptide (MDP) and bacteria-derived
single-stranded DNA fragments, with potential immunomodulating, immunoadjuvant and
antineoplastic activities. Upon administration of NY-ESO-1 protein/microparticle MDP/bacterial
DNA-containing MIS416 vaccine, MIS416 localizes in and is taken up mainly by the liver,
thereby forming a liver depot. MIS416 is then taken up by immune cells, such as monocytes
and dendritic cells (DCs), where MDP and the bacterial DNA target and bind to the
cytosolic innate pattern recognition receptors (PRRs) nucleotide-binding oligomerization
domain-containing protein 2 (NOD2), and toll-like receptor 9 (TLR9), respectively.
The simultaneous binding and activation of both NOD2 and TLR9, leads to activation
of both NOD2 and TLR9 signaling pathways. This stimulates the innate immune system,
induces secretion of cytokines, particularly interferon (IFN), and modulates the activation
of various immune cells. In the presence of the NY-ESO-1 peptide, MIS416 enhances
the cytotoxic T-lymphocyte (CTL)-mediated immune response against NY-ESO-1, resulting
in an increased anti-tumor immune response. NY-ESO-1 is expressed in normal testes
and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation
and survival.;
NCI Metathesaurus CUI : CL512226;
Origin ID : C128887;
UMLS CUI : C4288621;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
